EZQUER, EDUARDO FERNANDO
Thumbnail Image
Preferred name
EZQUER, EDUARDO FERNANDO
Main Affiliation
Email
eezquer@udd.cl
ORCID
Scopus Author ID
8614146900

Research Output

2024 2024 2023 2023 2022 2022 2021 2021 2020 2020 2019 2019 2018 2018 2017 2017 2016 2016 2015 2015 0.0 0.0 0.2 0.2 0.4 0.4 0.6 0.6 0.8 0.8 1.0 1.0

Filters

1
3
3
Reset filters

Settings
Now showing 1 - 3 of 3
No Thumbnail Available
Publication

The Immunoregulatory and Regenerative Potential of Activated Human Stem Cell Secretome Mitigates Acute-on-Chronic Liver Failure in a Rat Model

2024 , Barbara Cuadra , Veronica Silva , HUANG, YA LIN , Yael Diaz , Claudio Rivas , Cristobal Molina , Valeska Simon , Maria Rosa Bono , Bernardo Morales , Mario Rosemblatt , Sebastian Silva , ACUÑA ASTUDILLO, RODRIGO ANTONIO , EZQUER, EDUARDO FERNANDO , EZQUER, EDUARDO MARCELO

Acute-on-chronic liver failure (ACLF) is a syndrome marked by sudden liver function decline and multiorgan failure, predominantly acute kidney injury (AKY), in patients with chronic liver disease. Unregulated inflammation is a hallmark of ACLF; however, the key drivers of ACLF are not fully understood. This study explores the therapeutic properties of human mesenchymal stem cell (MSC) secretome, particularly focusing on its enhanced anti-inflammatory and pro-regenerative properties after the in vitro preconditioning of the cells. We evaluated the efficacy of the systemic administration of MSC secretome in preventing liver failure and AKI in a rat ACLF model where chronic liver disease was induced using by the administration of porcine serum, followed by D-galN/LPS administration to induce acute failure. After ACLF induction, animals were treated with saline (ACLF group) or MSC-derived secretome (ACLF-secretome group). The study revealed that MSC-secretome administration strongly reduced liver histological damage in the ACLF group, which was correlated with higher hepatocyte proliferation, increased hepatic and systemic anti-inflammatory molecule levels, and reduced neutrophil and macrophage infiltration. Additionally, renal examination revealed that MSC-secretome treatment mitigated tubular injuries, reduced apoptosis, and downregulated injury markers. These improvements were linked to increased survival rates in the ACLF-secretome group, endorsing MSC secretomes as a promising therapy for multiorgan failure in ACLF.

View
No Thumbnail Available
Publication

Endovenous Administration of Bone Marrow-Derived Multipotent Mesenchymal Stromal Cells Prevents Renal Failure in Diabetic Mice

2009 , EZQUER, EDUARDO FERNANDO , EZQUER, EDUARDO MARCELO , Valeska Simon , Fabian Pardo , Alejandro Yañez , Daniel Carpio , CONGET MOLINA, PAULETTE ANDREA

View
No Thumbnail Available
Publication

The Antidiabetic Effect of MSCs Is Not Impaired by Insulin Prophylaxis and Is Not Improved by a Second Dose of Cells

2011 , EZQUER, EDUARDO FERNANDO , EZQUER, EDUARDO MARCELO , Valeska Simon , CONGET MOLINA, PAULETTE ANDREA , Kathrin Maedler

View